
0:00
2:14
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Flere episoder fra "Pharmaceutical Executive"



Gå ikke glip af nogen episoder af “Pharmaceutical Executive” - abonnér på podcasten med gratisapp GetPodcast.








